Recombinant human endothelial cell growth factor
    2.
    再颁专利
    Recombinant human endothelial cell growth factor 有权
    重组人内皮细胞生长因子

    公开(公告)号:USRE37850E1

    公开(公告)日:2002-09-17

    申请号:US09538857

    申请日:2000-03-28

    IPC分类号: A61K3827

    摘要: Endothelial cell growth factor is achieved through the application of recombinant DNA technology to prepare cloning vehicles encoding the ECGF protein and procedures are disclosed for recovering ECGF protein essentially free of other proteins of human origin. The product is useful for, among other purposes, diagnostic applications and as potential in the treatment of damaged blood vessels or other endothelial cell-lined structures.

    摘要翻译: 内皮细胞生长因子通过应用重组DNA技术来制备编码ECGF蛋白质的克隆载体,公开了用于回收基本上不含人源蛋白质的ECGF蛋白质的方法。 该产品除了其它目的之外还可用于诊断应用,并且用于治疗损伤的血管或其它内皮细胞内衬结构的潜力。

    Method of preparing organs for vitrification
    4.
    发明授权
    Method of preparing organs for vitrification 失效
    玻璃化器官的制备方法

    公开(公告)号:US5723282A

    公开(公告)日:1998-03-03

    申请号:US292001

    申请日:1994-08-18

    IPC分类号: A01N1/02

    摘要: The invention relates to the field of organ and tissue perfusion. More particularly, the present invention relates to a method for preparing organs, such as the kidney and liver, for cryopreservation through the introduction of vitrifiable concentrations of cryoprotectant into them. To prepare the organ for cryopreservation, the donor human or animal, is treated in the usual manner and may also be treated with iloprost, or other vasodilators, and/or transforming growth factor .beta.1. Alternatively, or additionally, the organ which is to be cryopreserved can be administered iloprost, or other vasodilators, and/or transforming growth factor .beta.1 directly into its artery. The invention also relates to preparing organs for transplantation by a method for the removal of the cryoprotectant therefrom using low (such as raffinose, sucrose, mannitol, etc.), medium (such as agents with intermediate molecular weights of around 600-2,000) and high (such as hydroxyethyl starch) molecular weight agents osmotic buffering agents. The invention is also directed to new post-transplantation treatments such as the use of transforming growth factor .beta.1, N-acetylcysteine and aurothioglucose. Further, the invention relates to a method of vitrification of organs comprising a multi-step method of introducing increasing concentrations of cryoprotectant with osmotic equilibration of the organ and decreases in temperature prior to perfusion with vitrifiable concentrations of cryoprotectant at about -5.degree. C. to -35.degree. C.

    摘要翻译: 本发明涉及器官和组织灌注领域。 更具体地,本发明涉及通过向其中引入可玻璃化浓度的冷冻保护剂来制备用于冷冻保存的器官如肾脏和肝脏的方法。 为了制备用于低温保存的器官,供体人或动物以常规方式治疗,并且还可以用伊洛前列素或其它血管扩张剂和/或转化生长因子β1治疗。或者或另外, 可以冷冻保存伊洛前列素或其他血管扩张剂,和/或将生长因子β1直接转化到其动脉中。 本发明还涉及通过使用低(例如棉子糖,蔗糖,甘露醇等)的培养基(例如具有约600-2,000中等分子量的试剂)从其中除去冷冻保护剂的方法来制备用于移植的器官和 高(如羟乙基淀粉)分子量试剂渗透缓冲剂。 本发明还涉及新的移植后治疗,例如使用转化生长因子β1,N-乙酰半胱氨酸和嘌呤硫代葡萄糖。 此外,本发明涉及一种器官玻璃化方法,其包括多步骤方法,其在器官的渗透平衡下引入增加浓度的冷冻保护剂,并在灌注之前温度降低,在约-5℃至可冷冻浓度的冷冻保护剂至 -35℃